LDL Receptor Under Ezetimibe and Simvastatin

• Status: Completed
• Trial end date: 2004-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to investigate the effects of the two lipid -lowering drugs, ezetimibe and simvastatin, on lipid metabolism in humans. In specific, the study will investigate in blood cells whether the enzyme that controls cholesterol synthesis, HMG-CoA reductase, and the receptor that takes up cholesterol from the blood, the LDL receptor, are changed during treatment with the aforementioned drugs.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Cologne
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Ezetimibe; Simvastatin

Criteria

Inclusion Criteria:

• healthy male subjects

• age between 18 and 60 years

• body mass index between 18.5 and 30 kg/m2

• LDL cholesterol smaller than 190 mg/dL

• triglicerides smaller than 250 mg/dL

• normal blood pressure

Exclusion Criteria:

• intake of lipid-lowering drugs

• excessive alcohol intake

• liver disease

• kidney disease

• coronary heart disease

• eating disorders

• diabetes or other endocrine disorders

• medications that interfere with lipid metabolism